NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Pierre Fabre Ltd
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
UNICANCER
H. Lee Moffitt Cancer Center and Research Institute
Pierre Fabre Medicament
M.D. Anderson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
Pierre Fabre Medicament